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1. Introduction 
Biosynthetic studies on basement membrane type 
IV collagen indicate that it is first synthesized as two 
different chains, procul (IV) and procr2(IV). The prefix 
‘pro’in these names denote the presence of non-helical 
globular end-regions in the molecule. Current data 
from pulsechase studies [1,2] show Iittle or no con- 
version of the pro-IV chains and it has been proposed 
that at least a portion of the non-helical end-region of 
the pro-IV chains are retained and participate in the 
3dimensional structure of basement membrane matrix 
[3,4]. Here we describe the preparation of antibodies 
directed against at least 1 co~agenase-resistant pepsin 
and cllymotrypsin-sensitive disulfide bonded end- 
region in each of the procrl (IV) and proa2(IV) chains. 
The tissue localization of the antigenic determinants 
is studied by immunofluorescence. Competition radio- 
immunoassay with these antibodies shows recognition 
of reduced and alkylated 7 S collagen, supporting the 
possibility that this recently identified collagen is a 
cross-linked domain of type IV collagen [5]. 
2. Materials and methods 
2.1. ~~~c~ti~~, and charac~e~z~~o~ #fan~~en~ 
[“4C]Proline-labeled pro-type IV collagen was 
extracted from organ cultures of the murine EHS sar- 
coma with 0.5 M acetic acid and purified by NaCl pre- 
cipitation as in [2]. This collagen shows in SDS-PAGE 
Abbrevations: BSA, bovine serum albumin; DTT, di~iot~i- 
tol; EDTA, ethylen~~~dete~aa~tic acid; NEM, N-ethyl- 
maleimide; PBS, phosphate-buffered saline; SDS-PAGE, 
sodium dodecyl sulfate polyacrylamide gel electrophoresis; 
TPCK, tosyl-L-phenylalanylchloromethane 
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after reduction the typical double band mobility cor- 
responding to the apparent Mr-value of 170 000 and 
185 000 and can be purified to homogeneity. The same 
procedure was used to obtain non-radiolabeled type IV 
collagen, except that the tumor tissue culture was car- 
ried out using a non-labeled prolinecontainingmedium 
(RPM1 1640). 
~sH]Mannose~abeled pro-type IV collagen was 
generously supplied by Dr C. Clark (Philadelp~a, PA). 
Pepsinized lens capsule collagen containing Cl, C 
and D chains was generously supplied by Dr E. Miller 
(Birmingham, AL). 
Type I collagen was extracted from guinea pig skin 
asin [6]. 
cwAcrB collagen was purified from human placentae 
obtained from normal deliveries as in [7]. 
Laminin was a generous gift of Dr V. Terranova 
(National Institute of Dental Research, NIH). 
Fibronectin was purified by gelatin column chro- 
matography from the culture media of human fibro- 
blasts 1891. 
2.2. Preparation and purification of antibodies 
New Zealand white adult rabbits were injected sub- 
cutaneously at 2 different sites on the back with 
0.1 mg of native pro-type IV collagen in 0.5 M acetic 
acid emulsi~ed with an equal volume of Freund’s 
complete adjuvant . Booster injections were repeated 
as above after intervals of 3 and 10 weeks. Blood was 
collected from ear veins and the serum was stored in 
aliquots at -70°C. Possible contaminant antibodies 
reacting against laminin were removed by passing the 
antiserum through a 5 mg la~nin-Sepharose affinity 
column prepared using 5 ml of CNBr-activated Sep- 
harose4B (Pharmacia). PBS (pH 7.4) was used as 
equilibrating and running buffer. In order to remove 
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antibodies binding to the pepsin-resistant region, the 
antibodies were further purified over an affinity column 
of 5 mg pepsin-treated type IV collagen, 1 mg Pl -P2 
fragments and 2 mg pepsinized lens capsule collagen 
bound to 5 ml of CNBr-activated Sepharose4B. 
2.3. Pro teoly tic modijka tion of an tigers 
Chymotrypsin-treated pro-type 1V collagen was 
prepared by incubating a solution of [‘4C]proline- 
labeled pro-type IV collagen with a high concentra- 
tion (0.1 %f> of chymotrypsin (approximate enzyme/ 
substrate ratio of 100/l) 4 h at 25”IC in 50 mM Tris- 
HCl, 10 mM CaC12, 0.2 M NaCl, pH 7.4. The reaction 
was stopped by adding an equal volume of 0.5% TPCK 
and storing the mixture at 4°C. This material showed 
in SDS-PAGE a double band pattern with an apparent 
M,-value approx. 5% lower than the original (fig.3A). 
Pepsin-treated type IV collagen was prepared by 
incubating overnight at 4°C [14C]proline-labeled pro- 
type IV collagen with 0.1% (final concn.) pepsin in 
0.5 M acetic acid. The reaction was stopped by neu- 
tralizing the solution. 
Native pepsin fragments Pl and P2 from mouse 
EHS tumor type IV collagen were generously supplied 
by Dr P. Fietzek (Piscataway, NJ). 
7 S collagen [lo] was generously supplied by Dr S. 
Dixit (Memphis, TN). This material was further reduced 
and alkylated as follows: 1 mg was solubilized in 1 ml 
of 8 M urea, 50 mM Tris, pH 8 at 4°C. Then DTT was 
added to a final concentration of 20 mM and the solu- 
tion was incubated at 37°C for 4 h and cY-iodoacet- 
amide was added to final concn. of 80 mM. After 1 h 
at room temperature the mixture was extensively dia- 
lyzed in 10 mM acetic acid and then in 1% BSA in PBS. 
By gel ele~trophoresis, in reduced form this material 
contained a family of components ranging in Mr 
between 200 000--250 000. 
Collagenase-treated pro-type IV collagen was pre- 
pared as in [l l] by incubating 30 000 cpm of [14C]- 
proline-labeled pro-type IV collagen for 16 h at 37°C 
with 100 U of collagenase Form III (Advanced Biofac- 
tures) in 0.4 ml of 50 mM Tris-HCI, 10 mM CaCl,, 
0.2 M NaCl, 5 mM NEM, pH 7.4. The reaction was 
stopped by adding 50 d of 0.3 M EDTA. 
CNBr peptides of pro-type IV collagen were pre- 
pared as in 112,131. 
2.4. Rad~o~mmu~oassays 
Binding reactions between labeled pro-type IV 
collagen and the antibodies in the presence or absence 
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of competitors were undertaken in tubes containing 
100 d of 1% BSA in PBS and 100 11 of antiserum 
diluted in normal rabbit serum; after 30 min of incu- 
bation at 4°C with 100~1 of conlpetitors (0.1 mgfml- 
10 ng/ml) diluted in 1% BSA in PBS, 100 ~1 of labeled 
pro-type IV collagen (3000-5000 cpm) were added 
and the mixture incubated overnight at 4°C. lmmuno- 
complexes were then separated from free antigen by 
precipitation with a second antibody (100 fi of 
50 ,ul/ml goat anti-rabbit IgG, light and heavy chains; 
Cappel). After 2 h incubation at room temperature, 
1 ml of cold saline solution was added and the mix- 
ture was then centrifuged at 1600 X g for 30 min. The 
precipitate was solubilized in 10 ml of Ultrafluor 
(National Diagnostic) and analyzed in a scintillation 
counter. Nonspeci~~ precipitation of labeled antigen 
was determined using either normal rabbit serum or 
1% BSA in PBS and was found to be approx. 10% of 
the total radioactivity added. 
2 5. Immunoflitorescence 
Frozen sections (7-l Ogm) of human tissue includ- 
ing amnion, thyroid, kidney, breast and skin were 
hydrated in PBS. Antiserum (approx. 50 fig/ml of 
protein) was applied and the section incubated for 
60min in a humidified chamber at room temperature. 
After extensive PBS washing fluorescineconjugated 
goat anti-rabbit antibody (Cappel) was applied. Fol- 
lowing a 30 min incubation at room temperature and 
additional PBS washing, the sections were coverslipped 
over l/9 glycerol/PBS and examined with a Ieitz 
epifluorescence Ortholux 2 microscope. Appropriate 
controls were prepared using preimmune rabbit serum 
and other non-reacting antisera. 
3. Results 
Antisera from rabbits immunized with whole 
prorul(IV) and procu2fIV) chains (fIg.1, insert A) 
contained antibodies directed against multiple anti- 
genie determinants, including determinants resistant 
to bacterial collagenase digestion. Immunoprecipita- 
tion (fig.1) of the labeled pro-type IV collagen chains 
was markedly reduced but not abolished by chymo- 
trypsin in pepsin treatment. Bacterial collagenase treat- 
ment of the antigen reduced precipitation to approx. 
60% of the radioactivity precipitated with the untreated 
antigen. The existence of multiple antigenic determi- 
nants was confirmed by the immunoprecipitation of 
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ANTISERUM DILUTION 
Fig.1. Binding of [14C]proIine-labeled pro-type IV collagen 
by antiserum to native pro-type IV collagen. The antigen was 
native (*), bacterial collagenase treated (r), pepsin treated 
(A) and chymotrypsin treated (0). Insert: (A) the native pro- 
type IV collagen used as immunogen (Jfr 170 000-185 000 
prooll(IV) and prool2(IV) chains) run in 5% SDS-PAGE; (B) 
CNBr peptide pattern of the immunogen, and (C) the immuno- 
precipitate of the CNBr peptides using the antiserum, run in 
12% SDS-PAGE. 
.’ 
,..’ 
0 i 
106 
INHIBITOR lngl 
185 
170 t: 
d 
A 6 C 
D E F G 
Fig.3. (A) 5% SDS-PAGE autoradiography of [‘4C]proline- 
labeled pro-type IV collagen: A, native form; B, following 
chymotrypsin digestion; C, following pepsin digestion. 
(B) 12% SDS-PAGE autoradiography of the same substrate 
as (A): D, after bacterial collagenase digestion; E, the same 
following DTT reduction; F, immunoprecipitate, with the 
purified antibodies of the bacterial collagenase digestion; 
G, the same following DTT reduction. 
Fig.2. Inhibition of binding of [“‘C]proline4abeled native 
pro-type IV collagen (insert A) by affinity purified antibodies. 
The competitors shown are: unlabeled native pro-type IV col- 
lagen (o), reduced and alkylated 7 S collagen (A), lens capsule 
collagen, Cl, C and D chains (o), Pl and P2 pepsin fragments 
of EHS tumor pro-IV (a) and laminin (0). Insert B: autoradio- 
graphy of theimmunoprecipitate of procul(IV) and procxZ(IV) 
obtained without competitors, run in 5% SDS-PAGE. 
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CNBr-derived peptides from the pro-IV chains (iig.1, 
inserts B,C). 
The antiserum was further purified through an 
affinity column containing bound pepsinized lens 
capsule type IV collagen composed of C 1, C and D 
chains [ 141, Pl and P2 fragments and pepsin-treated 
type IV collagen from EHS sarcoma. The eluted 
unbound antibodies were tested for their specificity 
using competition radioimmunoassay. As shown in 
fig.2 immunoprecipitation of the tracer antigen was 
competitively inhibited by whole pro-type IV chains 
and by reduced and alkylated 7 S collagen. Bacterial 
collagenase-resistant fragments compete for the tracer 
with an efficiency about 5-times higher than the 
reduced and alkylated 7 S (data not shown). No com- 
petition is shown by unreduced 7 S collagen, Pl in 
P2 chains [ 15,161 from pepsinized EHS tumor pro-IV, 
nor by pepsinized lens capsule collagen, types 1, III or 
V collagen, fibronectin or laminin. Labeled laminin 
was not precipitated by the antibodies. 
The antibodies precipitated both procul(IV) and 
procu2(IV) chains and the ratio of the 2 did not vary 
at different antibody dilutions (fig.2, inserts A,B). 
Immunoprecipitation studies were also performed on 
bacterial collagenase digests of pro-IV chains. As shown 
in fig3B at least 5 major fragments of bacterial col- 
lagenase digest are identified by 12% SDS-PAGE. Two 
major disulfide boundcontaining components are 
estimated to be of Mr 67 000 and 59 000 without 
reduction and 23 000 and 18 000 after reduction. 
Another major component migrates with a Mr-value 
of 12 000 before reduction; after reduction this com- 
ponent migrates with the front. Two minor compo- 
nents are also present which are not affected by reduc- 
tion. All of the major components resistant to bacte- 
rial collagenase are precipitated by the antibodies. 
The affinity purified antibodies to the bacterial col- 
lagenase resistant determinants were used to study 
the localization of this antigen in tissue basement 
membranes. Using indirect immunofluorescence tech- 
nique the antibodies reacted with amnion (fig.4) thy- 
roid, breast and skin basement membranes. 
4. Discussion 
Type IV collagen can be isolated from tissue rich 
in basement membrane either by pepsin or acetic acid 
extraction: The former method extracts a family of 
collagenous fragments ranging in M,-value from 
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Fig.4. Indirect immunofluorescence of whole basement mem- 
brane from fresh human amnion showing intense localization 
with antibodies to collagenase-resistant terminal regions of 
native pro-type IV collagen (87.5X). 
15 000-140000 [3], the latter method yields 2 chains 
of 140 000 and 160 000 [ 151. Biosynthetic data have 
more recently shown that type IV collagen is synthe- 
sized as chains of 170 000-I 85 000 Mr. As an 
approach to studying the actual molecular form of 
type IV collagen in the tissue we have developed anti- 
bodies to the bacterial collagenase-resistant end- 
regions of the 170 000-I 85 000 M, chains. 
Type IV collagen has previously been shown to 
contain multiple antigenic determinants both in the 
helical and non-helical collagenase-resistant regions 
[ 161. In the present study, rabbit antiserum produced 
against the 2 pro-IV chains also recognizes multiple 
antigenic determinants,as hown in fig.1 where at least 
8 pro-IV CNBr peptides are immunoprecipitated with 
the antiserum. In order to estimate the location of 
these determinants the antigen was subjected to en- 
zyme treatments. Chymotrypsin treatment reduced 
the antibody binding to a greater degree than pepsin 
or bacterial collagenase (fig.1). Clark et al. (personal 
communication) showed that chymotrypsin treatment 
of the native parietal yolk sac pro-IV molecules yields 
a 5-10% reduction in the M,-value of both chains. We 
have confirmed this findings using the EHS sarcoma- 
derived pro-type IV (flg.3A). Thus a major antigenic 
determinant is chymotrypsin sensitive and does not 
reside on a major central structural portion of pro-IV 
collagen. 
To further study these determinants the antiserum 
was processed in an affinity column to remove ail anti- 
bodies directed against the pepsin-resistant domains. 
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Table 1 
Immunoprecipitation of [ 3H]mannose-labeled type IV collagen using affinity 
purified antibodies 
May 1981 
Substrate Precipitate (cpm) % of control 
Control pro-type IV collagena 2350 100 
After bacterial collagenase treatmentb 2338 100 
After chymotrypsin treatmentC 335 14 
a The background using preimmune serum was approx. 25% of the control precip- 
itate 
b The total amount of antigen radioactivity was 5000 
’ EDTA and TPCK used to stop the reactions 2 and 3, respectively, were included 
in the controls 
The resulting antibodies precipitated both pro-IV 
chains and such precipitation was not competitively 
inhibited by pepsinized or chymotrypsin-treated type 
IV collagen. Moreover, bacterial collagenase-resistant 
fragments of the molecules were precipitated by these 
antibodies (Bg.3B). These fragments were derived from 
the pro-IV chains since we verified that the labeled 
antigen did not contain contaminating non-collagenous 
labeled proteins such as laminin [ 171. The bacterial 
collagenase-resistant fragments obtained are similar 
as in [ 181. These investigators described a single bac- 
terial collagenase-resistant peak on 8% agarose, with 
an apparent M,-value of 70 000; after reduction the 
peak shifted to a lower value. They also noted addi- 
tional smaller Mr components. The pattern of the 
present material in SDS-PAGE consists of 2 fragments 
in the range of Mr 59 000 and 67 000 which are 
decreased to 18 000 and 23 000 after reduction. This 
decrease to l/3 in M,-value is consistent with 2 disul- 
fide-bounded tripeptides. The present study also iden- 
tities a major 12 000 Mr bacterial collagenase-resistant 
fragment which migrates with the front after reduc- 
tion. If the 2 chains are in separate molecules as in 
[ 191 then the present antibodies must recognize at 
least 1 region in each molecule to precipitate both 
chains. 
Radioactive proteins were precipitated from man- 
nose-labeled pro-IV chains before and after treatment 
with bacterial collagenase (table 1). It is known for 
other collagens that mannose is present only in the 
globular terminal region of procollagen [20,21]. 
Assuming an analogous distribution of mannose for 
pro-type IV collagen, the present data suggest he 
existence of collagena:e-resistant sugar containing 
terminal regions in both proal and proa2(IV). 
The recently characterized 7 S basement mem- 
brane collagen without reduction shows less than 5% 
competition for these antibodies. After reduction and 
alkylation 7 S competes completely at a concentration 
15times greater than native pro-type IV. This result 
is in agreement with the hypothesis that 7 S is a domain 
of type IV collagen in which 4 triple helical molecules 
are held together by disulfide bridges and other cova- 
lent cross-links [5]. 
The purified antibodies specific for the terminal 
regions of pro-IV reacted specifically with the basement 
membrane in a wide variety of tissues (fig.4). These 
results support previous studies which propose that 
type IV collagen retains noncollagenous terminal 
regions within the tissue basement membrane matrix 
[ 11. Whether or not the molecular form of type IV 
collagen may vary in different tissue basement mem- 
branes during various pathologic conditions [22] 
remains to be determined. The present antibodies may 
be useful to address this question. 
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